`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case IPR2020-01341
`Patent 8,142,413
`
`
`
`
`PATENT OWNER’S UNOPPOSED MOTION TO FILE UNDER SEAL
`PURSUANT TO 37 C.F.R. §§ 42.14 AND 42.54
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Patent Owner respectfully
`
`submits this Patent Owner’s Unopposed Motion to File Under Seal, requesting that
`
`the following information remain under seal: portions of Patent Owner’s Response,
`
`portions of Patent Owner’s Request for Preliminary Guidance on Contingent
`
`Motion to Amend U.S. Patent No. 8,142,413 Under 37 C.F.R. § 42.121, and
`
`Exhibits 2058, 2139, 2140, 2141, 2153, and 2154 filed therewith. The under-seal
`
`version of the Patent Owner Response and Patent Owner’s Request for Preliminary
`
`Guidance on Contingent Motion to Amend U.S. Patent No. 8,142,413 Under 37
`
`C.F.R. § 42.121, along with the identified under-seal exhibits, are being filed
`
`concurrently with this motion.
`
`Patent Owner has conferred with the Petitioner, and the Petitioner does not
`
`oppose this motion to seal.
`
`The Patent Owner and Petitioner have agreed to a stipulated Joint Protective
`
`Order attached hereto as Appendix A. Patent Owner respectfully requests that the
`
`Board enter that stipulated Joint Protective Order in the above captioned case to
`
`govern treatment of the documents and information identified herein.
`
`I.
`
`Good Cause
`
`For good cause, the Board may “issue an order to protect a party or person
`
`from disclosing confidential information.” 37 C.F.R. § 42.54. The rules “identify
`
`confidential information in a manner consistent with Federal Rule of Civil
`
`2
`
`
`
`Procedure 26(c)(1)(G), which provides for protective orders for trade secret or
`
`other confidential research, development, or commercial information.” Office
`
`Patent Trial Practice Guide, 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).
`
`Each of the sets of information below meets this standard, and for the
`
`reasons explained there is good cause for why those documents should remain
`
`under seal.
`
`A. Under-Seal Version of Patent Owner’s Response and Request for
`Preliminary Guidance on Contingent Motion to Amend
`
`Patent Owner has filed under-seal its Patent Owner Response and Patent
`
`Owner’s Request for Preliminary Guidance on Contingent Motion to Amend U.S.
`
`Patent No. 8,142,413 Under 37 C.F.R. § 42.121, as well as public, redacted
`
`versions of both Papers. The redacted portions on pages 52, 54, and 57 of the
`
`Patent Owner Response and page 22 of Patent Owner’s Request for Preliminary
`
`Guidance on Contingent Motion to Amend U.S. Patent No. 8,142,413 Under 37
`
`C.F.R. § 42.121 contain confidential Patent Owner sales data regarding GuideLiner
`
`revenue and units sold, as well as reflect licensing strategy. The remaining
`
`redacted portions reflect information that Petitioner Medtronic has designated as
`
`confidential under the district court protective order governing the parties in
`
`parallel litigation in the District of Minnesota.
`
`All of this information fits squarely within the kinds of information that the
`
`Trial Practice guide considers to be “confidential information,” such as
`
`3
`
`
`
`“confidential research, development, or commercial information.” 77 Fed. Reg.
`
`48756, 48760.
`
`There is good cause for keeping the redacted information contained in Patent
`
`Owner’s Response under seal. Publicly revealing the sensitive, competitive
`
`information could put the parties at a disadvantage in the marketplace.
`
`B.
`
`Exhibit 2058: Confidential Presentation
`
`Exhibit 2058, filed under seal, is a Vascular Solutions PowerPoint. This
`
`presentation reflects commercially sensitive discussions with a competitor, and
`
`includes commercially sensitive financial information regarding Patent Owner’s
`
`business. This information fits squarely within the kinds of information that the
`
`Trial Practice guide considers to be “confidential information,” such as
`
`“confidential . . . commercial information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping Exhibit 2058 under seal. Publicly revealing
`
`the commercially sensitive discussions and Patent Owner’s commercially sensitive
`
`financial information could put Patent Owner (and possibly a competitor) at a
`
`competitive disadvantage in the marketplace. Additionally, Petitioners do not
`
`oppose this information remaining under seal.
`
`
`
`C. Exhibits 2139-2141: Engineering Drawings
`
`Exhibits 2139, 2140, and 2141, filed as protective order material, are
`
`documents that were designated confidential in the case of QXMédical, LLC v.
`
`4
`
`
`
`Vascular Solutions, LLC, et al., 0:17-cv-01969-PJS-TNL (D. Minn.). These
`
`documents contain confidential information about Patent Owner’s product design
`
`and manufacture specifications. This information fits squarely within the kinds of
`
`information that the Trial Practice guide considers to be “confidential
`
`information,” such as “confidential research, development, or commercial
`
`information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for Patent Owner’s confidential product design and
`
`manufacture specifications under seal. Publicly revealing the sensitive,
`
`competitive information would put Patent Owner at a disadvantage in the
`
`marketplace.
`
`D. Exhibit 2153: Under Seal Declaration of Steve Jagodzinski
`
`Exhibit 2153 is the under seal, unredacted version of the Declaration of
`
`Steve Jagodzinski. Patent Owner has also filed a public, redacted version of this
`
`exhibit at Exhibit 2152. The under seal, redacted portions of Mr. Jagodzinski’s
`
`declaration summarize and discuss confidential, internal, proprietary data
`
`regarding GuideLiner revenue, units sold, and licensing strategy. This information
`
`fits squarely within the kinds of information that the Trial Practice guide considers
`
`to be “confidential information,” such as “confidential research, development, or
`
`commercial information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping the redacted information contained in
`
`5
`
`
`
`Exhibit 2153 under seal. Publicly revealing the commercially sensitive
`
`information noted above would put Patent Owner at a competitive disadvantage in
`
`the marketplace.
`
`E.
`
`Exhibit 2154: Confidential GuideLiner Revenue/Units Sold Data
`
`Exhibit 2154, filed under seal, is consists of internal, confidential,
`
`proprietary data showing GuideLiner revenue and units sold. This information fits
`
`squarely within the kinds of information that the Trial Practice guide considers to
`
`be “confidential information,” such as “confidential research, development, or
`
`commercial information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping Exhibit 2154 under seal. Publicly revealing
`
`the commercially sensitive information noted above would put Patent Owner at a
`
`competitive disadvantage in the marketplace.
`
`II. Certification of Conference
`
`Pursuant to 37 C.F.R. §§ 42.54(a), Patent Owner certifies that it has in good
`
`faith conferred with Petitioners’ counsel. Petitioners’ counsel does not oppose this
`
`motion to seal.
`
`Both Petitioners and Patent Owner agree to abide by the parties’ stipulated
`
`Protective Order pending a decision by the Board on the motion for entry thereof.
`
`6
`
`
`
`Request for Conference Call with the Board
`
`Should the Board not be inclined to grant the present Unopposed Motion to
`
`File Under Seal, Patent Owner hereby requests a conference call with the Board to
`
`discuss any concerns prior to the Board issuing a decision on the Motion.
`
`III. Conclusion
`
`Patent Owner respectfully requests that the Board grant this Unopposed
`
`Motion to File Under Seal, and keep the following documents under seal: the
`
`under-seal, unredacted version of the Patent Owner Response, Patent Owner’s
`
`Request for Preliminary Guidance on Contingent Motion to Amend U.S. Patent
`
`No. 8,142,413 Under 37 C.F.R. § 42.121, and Exhibits 2058, 2072, 2139, 2140,
`
`2141, 2153, and 2154.
`
`Patent Owner also requests that the Board enter the stipulated Joint
`
`Protective Order attached as Appendix A.
`
`
`
`7
`
`
`
`Dated: May 14, 2021.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/ J. Derek Vandenburgh /
`J. Derek Vandenburgh (Lead Counsel)
`Registration No. 32,179
`Carlson, Caspers, Vandenburgh
` & Lindquist, P.A.
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`Telephone: (612) 436-9600
`Facsimile: (612) 436-9650
`Email:
`DVandenburgh@carlsoncaspers.com
`
`Lead Counsel for Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8
`
`
`
`CERTIFICATION OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e) and the agreement of the parties, the
`
`
`
`undersigned certifies that on May 14, 2021, a true and correct copy of the
`
`foregoing PATENT OWNER’S UNOPPOSED MOTION TO FILE UNDER SEAL
`
`PURSUANT TO 37 C.F.R. §§ 42.14 AND 42.54 was served via electronic mail
`
`upon the following:
`
`Cyrus A. Morton (Reg. No. 44,954)
`Sharon Roberg-Perez (Reg. No. 69,600)
`Christopher A. Pinahs (Reg. No. 76,375)
`Robins Kaplan LLP
`800 LaSalle Avenue, Suite 2800
`Minneapolis, MN 55401
`Phone: 349-8500
`Fax: 612-339-4181
`Email: Cmorton@robinskaplan.com
`Email: Sroberg-perez@robinskaplan.com
`Email: Cpinahs@robinskaplan.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`/J. Derek Vandenburgh/
`J. Derek Vandenburgh (Lead Counsel)
`
`
`
`
`
`
`
`
`
`
`
`
`9
`
`
`
`Appendix A
`Appendix A
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case IPR2020-01342
`U.S. Patent No. 8,142,413
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`JOINT PROTECTIVE ORDER
`
`
`
`
`
`This Protective order governs the treatment and filing of confidential information,
`
`including documents and testimony.
`
`1. Confidential information shall be clearly marked “PROTECTIVE
`
`ORDER MATERIAL.”
`
`2. Access to confidential information is limited to the following individuals
`
`who have executed the acknowledgment appended to this order:
`
`(A) Party Representatives. Outside counsel for a party in the above-
`
`captioned proceeding.
`
`(B) Experts. Retained experts of a party in the proceeding who further
`
`certify in the Acknowledgement that they are not a competitor to any party,
`
`or a consultant for, or employed by, such a competitor with respect to the
`
`subject matter of the proceeding.
`
`(C) In-house counsel. Each party may designate up to 2 in-house counsel
`
`who are involved in this inter partes review, provided such in-house counsel
`
`has signed the Acknowledgement attached hereto as Exhibit A, their duties
`
`require them to assist outside counsel in this inter partes review, they do not
`
`have competitive decision making responsibilities or opportunity, and they
`
`are not involved in the prosecution or the supervision of the prosecution of
`
`any patents for any party. Petitioners designate: Chad Hanson and Matt
`
`Anderson. Patent Owner designates: Howard Cyr.
`
`
`
`(D) Support Personnel. Administrative assistants, clerical staff, court
`
`reporters and other support personnel of the foregoing persons who are
`
`reasonably necessary to assist those persons in the proceeding shall not be
`
`required to sign an Acknowledgement, but shall be informed of the terms
`
`and requirements of the Protective Order by the person they are supporting
`
`who receives confidential information.
`
`(E) The Office. Employees and representatives of the United States Patent
`
`and Trademark Office who have a need for access to the confidential
`
`information shall have such access without the requirement to sign an
`
`Acknowledgement. Such employees and representatives shall include the
`
`Director, members of the Board and their clerical staff, other support
`
`personnel, court reporters, and other persons acting on behalf of the Office.
`
`
`
`3. Persons receiving confidential information shall use reasonable efforts to
`
`maintain the confidentiality of the information, including:
`
`(A) Maintaining such information in a secure location to which persons not
`
`authorized to receive the information shall not have access;
`
`(B) Otherwise using reasonable efforts to maintain the confidentiality of the
`
`
`
`information, which efforts shall be no less rigorous than those the recipient
`
`uses to maintain the confidentiality of information not received from the
`
`disclosing party;
`
`(C) Ensuring that support personnel of the recipient who have access to the
`
`confidential information understand and abide by the obligation to maintain
`
`the confidentiality of information received that is designated as confidential;
`
`and
`
`(D) Limiting the copying of confidential information to a reasonable number
`
`of copies needed for conduct of the proceeding and maintaining a record of
`
`the locations of such copies.
`
`
`
`4. Persons receiving confidential information shall use the following
`
`procedures to maintain the confidentiality of the information:
`
`(A) Documents and Information Filed With the Board.
`
`(i) A party may file documents or information with the Board along with a
`
`Motion to Seal. The Motion to Seal should provide a non-confidential
`
`description of the nature of the confidential information that is under seal,
`
`and set forth the reasons why the information is confidential and should not
`
`be made available to the public. A party may challenge the confidentiality of
`
`the information by opposing the Motion to Seal. The submission shall be
`
`
`
`treated as confidential and remain under seal, unless the Board determines
`
`that the documents or information do not to qualify for confidential
`
`treatment. The information shall remain under seal unless, upon motion of a
`
`party and after a hearing on the issue, or sua sponte, the Board determines
`
`that some or all of the information does not qualify for confidential
`
`treatment.
`
`(ii) Where confidentiality is alleged as to some but not all of the information
`
`submitted to the Board, the submitting party shall file confidential and
`
`non-confidential versions of its submission, together with a Motion to Seal
`
`the confidential version setting forth the reasons why the information
`
`redacted from the non-confidential version is confidential and should not be
`
`made available to the public. A party may challenge the confidentiality of
`
`the information by opposing the Motion to Seal. The non-confidential
`
`version of the submission shall clearly indicate the locations of information
`
`that has been redacted. The confidential version of the submission shall be
`
`filed under seal. The redacted information shall remain under seal unless,
`
`upon motion of a party and after a hearing on the issue, or sua sponte, the
`
`Board determines that some or all of the redacted information does not
`
`qualify for confidential treatment.
`
`(B) Documents and Information Exchanged Among the Parties. Documents
`
`
`
`(including deposition transcripts) and other information designated as
`
`confidential that are disclosed to another party during discovery or other
`
`proceedings before the Board shall be clearly marked as “PROTECTIVE
`
`ORDER MATERIAL” and shall be produced in a manner that maintains its
`
`confidentiality.
`
`
`
`5. Confidential Testimony. Any person providing testimony in the
`
`proceeding may, on the record during the testimony, preliminarily designate the
`
`entirety of the person’s testimony and all transcriptions thereof as confidential,
`
`pending further review. Within ten days of the receipt of the transcript of the
`
`testimony, that person, or that person’s representative, shall advise the opposing
`
`party of those portions of the testimony to which a claim of confidentiality is to be
`
`maintained, and the reasons in support of that claim. Such portions shall be treated
`
`as confidential and maintained under seal in any filings to the Board unless, upon
`
`motion of a party and after a hearing on the issue, or sua sponte, the Board
`
`determines that some or all of the redacted information does not qualify for
`
`confidential treatment.
`
`
`
`6. Within 60 days after the final disposition of this action, including the
`
`
`
`exhaustion of all appeals and motions, each party receiving confidential
`
`information must certify the destruction of, all copies of the confidential
`
`information to the producing party.
`
`
`
`7. Each party will produce all materials produced or filed during the course
`
`of the above-captioned proceeding in the litigation captioned as Vascular Solutions
`
`LLC et al. v. Medtronic Inc. et al., No. 19-cv-01760-PJS-TNL with litigation Bates
`
`stamps within 14 days after filing or serving such information in the above-
`
`captioned proceeding.
`
`
`
`8. The Parties agree to abide by this Protective Order pending a decision by
`
`the Board on the Parties’ motion for entry thereof.
`
`
`
`9. Standard Acknowledgement of Protective Order. The following form will
`
`be used to acknowledge a protective order and gain access to information covered
`
`by the protective order:
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case Nos. IPR2020-01341, -01342, -01343,
`-01344
`
`
`Standard Acknowledgment for Access to Protective Order Material
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I __________________________________________, affirm that I have
`read the Protective Order; that I will abide by its terms; that I will use the
`confidential information only in connection with this proceeding and for no other
`purpose; that I will only allow access to support staff who are reasonably necessary
`to assist me in this proceeding; that prior to any disclosure to such support staff I
`informed or will inform them of the requirements of the Protective Order; that I am
`personally responsible for the requirements of the terms of the Protective Order
`and I agree to submit to the jurisdiction of the Office and the United States District
`Court for the Eastern District of Virginia for purposes of enforcing the terms of the
`Protective Order and providing remedies for its breach.
`
`
`_______________________________________ Date: ______________
`[Signature]
`
`
`
`